Abstract
The authors present data showing that a PSA slope <2 pg/mL/mo obtained using a new ultrasensitive assay (NADiA ProsVue) predicts a decreased risk of prostate cancer recurrence after RP. Disease recurrence was defined very strictly as positive biopsy findings, radiographic evidence of disease, or death from prostate cancer. Biochemical failure alone was not considered clinical disease recurrence.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
